Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Humacyte, Inc. (HUMA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.39-0.55 (-5.03%)
At close: 04:00PM EST
10.00 -0.39 (-3.75%)
After hours: 06:05PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.94
Open10.94
Bid10.00 x 1000
Ask10.50 x 900
Day's Range9.87 - 10.94
52 Week Range8.61 - 17.45
Volume531,623
Avg. Volume397,715
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
  • GlobeNewswire

    Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association’s Scientific Sessions 2021

    -- Patency and host cell remodeling of the HAV were observed in all study implants – -- Preclinical study is one component of Humacyte’s expansion of the testing of the HAV in a broader cardiac bypass surgery application – DURHAM, N.C., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced positive results from a preclinical study of the sm

  • GlobeNewswire

    Humacyte Presents New 12-Month Data from HAVs™ Produced Using Commercial-Scale Manufacturing System

    – Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency observed at 12 months post-implantation – – Data presented today in keynote presentation at 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS2021) – Durham, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology plat

  • GlobeNewswire

    Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights

    -- Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds -- -- Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™) and other engineered tissue platform applications -- DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial resu

Advertisement
Advertisement